DDrare: Database of Drug Development for Rare Diseases

40. 高安動脈炎
［臨床試験数：22，薬物数：46（DrugBank：20），標的遺伝子数：22，標的パスウェイ数：111］

Searched query = "Takayasu arteritis", "Aortitis syndrome", "Pulseless disease"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.

Drug = AZA; Acetate; Adalimumab; Anti-thymocyte globulin; CYC; Clofarabine; Cyclophosphamide; Cyclosporine; DCB; Filgrastim; Glucocorticoids; INFLIXIMAB; Infliximab; Leflunomide; Leflunomide 10mg Tab; MMF; MTX; Methotrexate; Methotrexate Tablets; Methylprednisolone; Naltrexone; Naltrexone Hydrochloride; Placebo; Prednisolone; Prednisone; Prednisone Acetate; Prednisone acetate; Prednisone, cyclophosphamide; Procedure: Autologous Peripheral Blood Stem Cell Transplantation; Procedure: Computed Tomography; Procedure: Digital substraction angiography (DSA); Procedure: Drug coated balloon (DCB); Procedure: Positron Emission Tomography; Radiation: Fluorine F 18 Clofarabine; Remicade; Remicade (anti tumor necrosis factor inhibitor); RoActemra; RoActemra 20mg/ml; TOCILIZUMAB; Tocilizumab; Tocilizumab (MRA-SC); Tofacitinib; Tofacitinib tablet; Upadacitinib; Yellow Fever Vaccine; Yellow Fever vaccine (17D)

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04564001 (ClinicalTrials.gov)	September 2020	21/9/2020	Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis	Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis	Takayasu Arteritis	Drug: Infliximab;Drug: Tocilizumab	Assistance Publique - Hôpitaux de Paris	NULL	Not yet recruiting	18 Years	N/A	All	50	Phase 2	NULL
2	EUCTR2018-003753-13-FR (EUCTR)	19/03/2019	13/12/2018	INTOReTAK : INfliximab and TOcilizumab in Refractory/relapsing TAKayasu arteritis	Multicentre, randomized, prospective trial comparing the efficacy and safety of Infliximab to tocilizumab in refractory or relapsing Takayasu arteritis	Patients with refractory or relapsing Takayasu Arteritis desease;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]	Trade Name: RoActemra 20mg/ml Product Name: Tocilizumab INN or Proposed INN: Tocilizumab Other descriptive name: TOCILIZUMAB Product Name: Infliximab INN or Proposed INN: INFLIXIMAB	ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS	NULL	Authorised-recruitment may be ongoing or finished			Female: yes Male: yes	50	Phase 3	France
3	NCT03192878 (ClinicalTrials.gov)	March 1, 2017	9/5/2017	Infliximab Biosimilar in Takayasu's Arteritis	A Prospective Observational Study of Infliximab Biosimilar in the Treatment of Takayasu's Arteritis Resistant to Corticosteroids and Conventional Immune-suppressive Treatments	Takayasu Arteritis	Drug: Infliximab	Ospedale San Raffaele	NULL	Recruiting	18 Years	N/A	All	30	N/A	Italy

No.

TrialID

Date_
enrollment

Date_
registration

Public_title

Scientific_title

Condition

Intervention

Primary_
sponsor

Secondary_
sponsor

Recruitment_
Status

Inclusion_
agemin

Inclusion_
agemax

Inclusion_
gender

Target_
size

Phase

Countries

NCT04564001
(ClinicalTrials.gov)

September 2020

21/9/2020

Multicentre, Randomized, Prospective Trial Evaluating the Efficacy and Safety of Infliximab to Tocilizumab in Refractory or Relapsing Takayasu Arteritis

Takayasu Arteritis

Drug: Infliximab;Drug: Tocilizumab

Assistance Publique - Hôpitaux de Paris

NULL

Not yet recruiting

18 Years

N/A

All

Phase 2

NULL

EUCTR2018-003753-13-FR
(EUCTR)

19/03/2019

13/12/2018

INTOReTAK : INfliximab and TOcilizumab in Refractory/relapsing TAKayasu arteritis

Multicentre, randomized, prospective trial comparing the efficacy and safety of Infliximab to tocilizumab in refractory or relapsing Takayasu arteritis

Patients with refractory or relapsing Takayasu Arteritis desease;Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]

Trade Name: RoActemra 20mg/ml
Product Name: Tocilizumab
INN or Proposed INN: Tocilizumab
Other descriptive name: TOCILIZUMAB
Product Name: Infliximab
INN or Proposed INN: INFLIXIMAB

ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS

NULL

Authorised-recruitment may be ongoing or finished

Female: yes
Male: yes

Phase 3

France

NCT03192878
(ClinicalTrials.gov)

March 1, 2017

9/5/2017

Infliximab Biosimilar in Takayasu's Arteritis

A Prospective Observational Study of Infliximab Biosimilar in the Treatment of Takayasu's Arteritis Resistant to Corticosteroids and Conventional Immune-suppressive Treatments

Takayasu Arteritis

Drug: Infliximab

Ospedale San Raffaele

NULL

Recruiting

18 Years

N/A

All

N/A

Italy